CHARLOTTE – Troutman Pepper Locke represented H.C. Wainwright & Co., the exclusive placement agent, in the closing of a registered public offering by Pasithea Therapeutics Corp. (Nasdaq: KTTA, KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of NF1-associated plexiform neurofibromas (NF1-PN). In the offering, the company sold 80,000,000 shares of common stock (or pre-funded warrants in lieu thereof) at $0.75 per share for gross proceeds of $60 million. For more information, see the press release.
The Troutman Pepper Locke team that advised H.C. Wainwright & Co. was led by David Wolpa and included Gabby Gaudet and Caitlin Oh. Rakesh Gopalan also advised on the transaction.
Consistently recognized as a top-tier practice, Troutman Pepper Locke’s corporate attorneys leverage broad experience and deep industry knowledge to help clients navigate global markets and achieve their capital-raising objectives. The firm’s capital markets team is regularly recognized in industry league table rankings released by LSEG and Bloomberg, maintaining top rankings internationally and in the Americas. They focus on minimizing regulatory and economic risks while positioning clients for potential opportunities. The firm represents domestic and foreign issuers, underwriters, selling and controlling shareholders, and other market participants in a wide range of capital markets transactions.
Troutman Pepper Locke
Troutman Pepper Locke helps clients solve complex legal challenges and achieve their business goals in an ever-changing global economy. With more than 1,600 attorneys in 30+ offices, the firm serves clients in all major industry sectors, with particular depth in energy, financial services, health care and life sciences, insurance and reinsurance, private equity, and real estate. Learn more at troutman.com.